Like Pinnacle 21

closed 10/4/2021 via GlobeNewswire

Certara, acquired Pinnacle 21

synopsis: Certara, Inc., a global leader in biosimulation, announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness.
buyer parent: EQT AB
buyer: Certara (:$261.77)
Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. "
target: Pinnacle 21
Pinnacle 21 is a global leader in software for preparing clinical trial data for regulatory submission. Their platform validates data quality and compliance with CDISC standards, enabling a clean data pipeline from worldwide sponsors to health authorities, including the FDA, PMDA and NMPA.
price ($mm)
$310
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/13/2019 via BusinessWire

Saama Technologies, will acquire Comprehend Systems, Inc.

synopsis: Saama Technologies, Inc., the advanced clinical data and analytics company, announced that it has signed a definitive agreement to acquire Comprehend Systems, Inc., a company that provides a suite of cloud applications and consulting services that dramatically improve the clinical trial process.
buyer: Saama Technologies
Saama Technologies is the advanced clinical data and analytics company, unleashing wisdom from data to deliver better actionable business outcomes for the life sciences industry. "
target: Comprehend Systems, Inc.
Comprehend provides a suite of cloud applications and consulting services that dramatically improve the clinical trial process. Their solutions deliver actionable risk and performance insights across studies, systems, sites, and vendors.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/21/2018 via BusinessWire

Anju Software, acquired MDCPartners

synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Belgium-based MDCPartners, a company that specializes in business intelligence data solutions for clinical trial optimization, medical expert identification and competitive intelligence.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by professionals with deep software domain expertise and a track record of building software platforms through strategic acquisitions and organic growth. "
target: MDCPartners
Based in Belgium, MDCPartners provides business intelligence solutions for clinical trial optimization, medical expert identification and competitive intelligence. MDC provides its clients with event-based tools to monitor and analyze an ever-expanding world of public and private data.
price ($mm)
rev ($mm)
$1,514
EBITDA ($mm)
$176
EV / rev
0.0x
EV / EBITDA
0.0x
announced 6/15/2016 via PR Newswire

The WIRB-Copernicus Group, will purchase Clinical Trial Applications from karmadata

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality of clinical research, will acquire from karmadata a suite of proprietary applications designed to facilitate the management of clinical trial data. karmadata is the market leader in clinical trial database and decision support applications.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
seller: karmadata
Karmadata is able to standardize and link the world's healthcare data ranging from leading open data sources to priva pharmacy and medical claims. Its propriety applications are designed to facilitate the management of clinical trial data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/6/2015 via BusinessWire

IMS Health Incorporated, acquired Dataline Software

synopsis: IMS Health has acquired Dataline Software, a leader in Big Data analytics for healthcare. U.K.-based Dataline has worked closely with life sciences companies, payers, healthcare authorities and academia to deliver tailored software for rapid analysis and elegant visualizations of large, complex healthcare data sets.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is an information and technology services company providing clients in the healthcare industry with solutions to measure and improve their performance. The company's IMS One™ cloud platform provides comprehensive insights into diseases, treatments, costs and outcomes. "
target: Dataline Software
Dataline is a software solutions company specializing in big-data analytics solutions for healthcare. They also provide consultancy, training, system implementation, application development and technical support to a wide and varied client base.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2014 via Company Press Release

ERT, acquired eClinical Insights, Inc.

synopsis: ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, announced the acquisition of eClinical Insights (eCI), an innovative provider of cloud-based clinical trials management software.
buyer parent: Genstar Capital LLC
buyer: ERT
ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data. "
target: eClinical Insights, Inc.
eClinical Insights® is a leading-edge provider of cloud-based clinical software that provides clinical research professionals with the strategic visibility to make rapid, data-driven decisions to positively impact the performance and cost of their clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/24/2009 via PR Newswire

OmniComm Systems, Inc., purchased EDC Solutions from eResearch Technology, Inc.

synopsis: OmniComm Systems, Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials, has acquired the EDC business of eResearchTechnology, Inc., a global provider of technology and services that enable life science industries worldwide to collect, interpret, and distribute cardiac safety and clinical data.
buyer: OmniComm Systems, Inc. (OTCPK:OMCM:$14,891.70)
OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. "
seller: eResearch Technology, Inc.
eResearchTechnology, Inc. (eRT) is a provider of technology-based products and services that enable the pharmaceutical, biotechnological, medical device, and contract resource companies to collect, interpret, and distribute cardiac safety and clinical data more efficiently.
price ($mm)[EV]
$2.02 [$0.87]
rev ($mm)
$6
EBITDA ($mm)
EV / rev
0.1x
EV / EBITDA
closed 7/15/2009 via BusinessWire

Merge Healthcare, acquired etrials, Inc.

synopsis: Merge Healthcare Inc., a leading health IT solutions provider, and etrials Worldwide, Inc., a leading provider of clinical trials software and services, announced the expiration of the exchange offer for the shares of etrials’ common stock by Merge Acquisition Corp. Merge now owns approximately 86% of the outstanding shares of Etrials common stock.
buyer: Merge Healthcare (MRGE:$227.59)
Merge Healthcare Incorporated builds software solutions that automate healthcare data and diagnostic workflow to build a better electronic record of the patient experience. "
target: etrials, Inc.
etrials has earned the loyalty of its healthcare partners by guiding them to simplify and accelerate the processes associated with collecting data in clinical trials. Using innovative technologies and proven business processes, etrials offers the most efficient data management products and services.
price ($mm)[EV]
$21 [$14]
rev ($mm)
$16
EBITDA ($mm)
EV / rev
0.9x
EV / EBITDA
closed 7/22/2009 via PR Newswire

Oracle Corporation, acquired Relsys International, Inc.

synopsis: Oracle Corporation has completed the acquisition of Relsys International, Inc. The combination of Oracle and Relsys is expected to deliver the only suite of software applications that supports end-to-end drug safety processes across clinical development, post-market surveillance and patient care.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is the world's largest enterprise software company. The company is a leading provider of systems software, including database management, application development, and application server software. "
target: Relsys International, Inc.
Relsys International is the leading global provider of drug safety and pharmacovigilance solutions that help pharmaceutical, biotech and medical device companies ensure regulatory compliance, streamline operations, and improve product safety.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/2/2018 via GlobeNewswire

OmniComm Systems, Inc., acquired Algorics

synopsis: OmniComm Systems, Inc., a leading strategic software solutions provider to the life sciences industry, has acquired Algorics, a company that provides innovative risk-based monitoring and clinical analytics solutions and software to the global life sciences industry with consistent and reliable quality.
buyer: OmniComm Systems, Inc. (OTCPK:OMCM:$14,891.70)
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. "
target: Algorics
Algorics brings together a team of highly experienced software and life science professionals, united behind a single goal: to provide innovative risk-based monitoring and clinical analytics solutions and software to the global life sciences industry with consistent and reliable quality.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/4/2021 via PR Newswire

Clarivate plc, acquired Bioinfogate S.L.

synopsis: Clarivate Plc, a global leader in providing trusted information and insights to accelerate the pace of innovation, has acquired Bioinfogate, a leading provider of analytics solutions in the life sciences and producer of the OFF-X™ portal.
buyer: Clarivate plc (:$1,614.03)
Clarivate is a global leader in providing solutions to accelerate the lifecycle of innovation. Clarivate helps customers discover, protect and commercialize their inventions using its trusted subscription and technology-based solutions coupled with deep domain expertise. "
target: Bioinfogate S.L.
Bioinfogate is a leading provider of analytics solutions in the life sciences and producer of the OFF-X portal, a safety intelligence solution aimed at empowering pharmaceutical organizations to identify toxicology and safety signals, mitigate safety liabilities and de-risk early-stage assets.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/16/2021 via BusinessWire

Exscientia, will acquire Allcyte

synopsis: UK-based Exscientia, a clinical stage pharmatech company, will acquire Allcyte, an Austrian leader in AI-based precision medicine. The combination expands Exscientia’s translational capabilities by enabling high content evaluation of individual patient biology in primary tumour tissues, rather than artificial cell lines or animal models.
buyer: Exscientia
Based in the UK, Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting. "
target: Allcyte
Based in Austria, Allcyte is a leader in artificial intelligence (AI) based precision medicine. Allcyte’s technology is designed to select the most promising drug candidates for clinical development in the right patient populations to maximise clinical study success rates and patient benefit.
price ($mm)
$61
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 5/30/2019 via BusinessWire

Evidera, will acquire Medimix International

synopsis: Evidera, a business unit of PPD, LLC, and a provider of evidence-based solutions demonstrating the real-world effectiveness and safety of health care products, will acquire Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic and medical device industries.
buyer parent: Carlyle Group
buyer: Evidera
Evidera, a PPD business unit, is a leading provider of evidence-based solutions to demonstrate the real-world effectiveness, safety and value of health care products. They help biopharmaceutical, biotechnology and medical device companies generate the evidence needed to optimize the market access. "
target: Medimix International
Medimix International specializes in providing business understanding, real-world evidence insights to the pharmaceutical and medical device industries. Medimix’s primary solution, LiveTracker™, is a cloud-based platform that provides real-time monitoring of clients’ particular therapeutic markets.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/28/2014 via Company Press Release

Medidata Solutions Worldwide, acquired Patient Profiles, LLC

synopsis: Medidata Solutions, the leading global provider of cloud-based solutions for clinical research in life sciences, announced it has acquired Patient Profiles, LLC. They are an early-stage software company focused on clinical data analytics in clinical trials.
buyer: Medidata Solutions Worldwide (MDSO:$660.00)
Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion. "
target: Patient Profiles, LLC
Patient Profiles, LLC was founded in 2013 to develop software to improve the efficiency of clinical trials. The Company’s “Patient Profiles” software makes individual reports for every patient in a clinical trial.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/3/2014 via PR Newswire

TrialScope, acquired PharmaCM

synopsis: TrialScope, a provider of clinical trial solutions and services, announced its acquisition of substantially all of the assets of Deloitte Analytics LLC, including the PharmaCM business which provides technology solutions for clinical trial registration and transparency.
buyer: TrialScope
TrialScope is the global leader in clinical trial transparency and compliance. TrialScope's tools and systems enable their customers to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater business success. "
target parent: Deloitte LLP
target: PharmaCM
PharmaCM is a content management platform designed specifically for the regulated environment of Life Sciences. The PharmaCM platform is the basis for a number of modules developed to address specific content management and workflow challenges across the clinical and regulatory content value chain.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/21/2014 via BusinessWire

Euroscript International SA, acquired Infotehna Group

synopsis: euroscript International S.A. has closed the acquisition of the Slovenia-based life sciences regulatory & compliance content management software vendor, INFOTEHNA Group LLC. INFOTEHNA is a leader in the development and delivery of regulatory compliance solutions for the life sciences industry.
buyer: Euroscript International SA
Euroscript is a leading provider in global content lifecycle management solutions. Euroscript divisions deliver comprehensive solutions that help customers design, build and run content management operations of all sizes. "
target: Infotehna Group
INFOTEHNA is a worldwide leader in the development and delivery of the most advanced enterprise-regulated content and process management, as well as regulatory compliance solutions for life sciences industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/7/2014 via PR Newswire

Decision Resources Group, acquired Relay Technology Management

synopsis: Piramal Enterprises' Information Management Subsidiary, Decision Resources Group, one of the world's leading research and advisory firms focusing on high-value healthcare insights and analytics, announced that it acquired Relay Technology Management, a data analytics company focused on the life-sciences industry.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Relay Technology Management
Relay Technology Management is a life sciences business intelligence software provider founded in 2008 with one core belief: that enabling data-driven decision-making via objective, standard asset valuation and trend analytics will lead to increased efficiency in drug development.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2020 via Company Press Release

Phlexglobal, acquired Cunesoft

synopsis: Phlexglobal, the leading provider of Trial Master File (TMF) software and expert services, has acquired Cunesoft, a European leader in cloud-based regulatory software solutions for the life sciences industry. Cunesoft offers a machine learning powered regulatory compliance software suite for compliant document, data and submission management.
buyer parent: Vitruvian Partners LLP
buyer: Phlexglobal
Phlexglobal is the world-leading specialist provider of electronic Trial Master File (eTMF) systems and services to the life sciences industry. Phlexglobal leverages authoritative TMF technologies and expert services to bring order, stability, and control to their client's Trial Master File. "
target: Cunesoft
Cunesoft is a European leader in cloud-based regulatory software solutions and services for all segments within the life sciences industry. Cunesoft offers a machine learning powered regulatory compliance software suite for compliant document, data and submission management.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 2/10/2016 via BNC Analysis

Fortune Bay Corp., will acquire Kneat Software

synopsis: Fortune Bay Corp. and Kneat Software ("Kneat") are pleased to announce that they have entered into a transaction agreement pursuant to which Fortune Bay will acquire 100% of Kneat. Kneat is a powerful software platform for Electronic Validation Life Cycle Management for Pharmaceutical, Biotech and Medical Device Manufacturers.
buyer: Fortune Bay Corp. (TSX:FOR:$0.00)
Fortune Bay is engaged in the exploration and potential development of two primary mining projects: the Goldfields project and the Ixhuatán project. The Goldfields project is a property located in northern Saskatchewan and consists of two gold deposits: the Box deposit and the Athona deposit. "
target: Kneat Software
Kneat, headquartered Ireland, is in the business of developing and marketing the Kneat Gx platform software that meets the stringent pharmaceutical industry regulatory requirements for all forms of validation, equipment changeover management, risk lifecycle management, change control and much more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/20/2016 via PR Newswire

Sparta Systems, Inc., acquired 123Compliance Corporation

synopsis: Sparta Systems, Inc., an industry pioneer and global leader in enterprise quality management software solutions, announced it has acquired 123Compliance, a leading provider of cloud-based complaint handling, quality management, regulatory reporting and document management systems for small and mid-sized pharmaceutical and medical device companies.
buyer parent: Thoma Bravo, LLC
buyer: Sparta Systems, Inc.
Sparta Systems, an industry pioneer and global leading provider of enterprise quality management software (EQMS) solutions, enables businesses to safely and efficiently deliver their products to market. Its TrackWise EQMS is used to manage compliance, reduce risk and improve safety. "
target: 123Compliance Corporation
123Compliance Corporation is the world's first fully cloud- and mobile-enabled enterprise quality management software company. It provides complaint handling, adverse event reporting, quality management, and device tracking built entirely on the Salesforce Platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/4/2021 via GlobeNewswire

Certara, acquired Pinnacle 21

synopsis: Certara, Inc., a global leader in biosimulation, announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness.
buyer parent: EQT AB
buyer: Certara (:$261.77)
Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. "
target: Pinnacle 21
Pinnacle 21 is a global leader in software for preparing clinical trial data for regulatory submission. Their platform validates data quality and compliance with CDISC standards, enabling a clean data pipeline from worldwide sponsors to health authorities, including the FDA, PMDA and NMPA.
price ($mm)
$310
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/4/2021 via GlobeNewswire

Certara, acquired Pinnacle 21

synopsis: Certara, Inc., a global leader in biosimulation, announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness.
buyer parent: EQT AB
buyer: Certara (:$261.77)
Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. "
target: Pinnacle 21
Pinnacle 21 is a global leader in software for preparing clinical trial data for regulatory submission. Their platform validates data quality and compliance with CDISC standards, enabling a clean data pipeline from worldwide sponsors to health authorities, including the FDA, PMDA and NMPA.
price ($mm)
$310
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/25/2020 via Company Press Release

Simcyp Limited, purchased Neurodegenerative Technology Assets from In Silico Biosciences, Inc.

synopsis: Certara, the global model-informed drug development and decision support leader, has acquired a range of neurodegenerative diseases modeling and simulation technology assets from In Silico Biosciences, Inc., a company that offers computer simulation support in drug development.
buyer parent: Certara
buyer: Simcyp Limited
Certara’s Simcyp division is a research-based company which provides modelling and simulation software to the pharmaceutical industry for use during drug development. "
seller: In Silico Biosciences, Inc.
The assets include a platform of multiple integrated quantitative systems pharmacology modules of brain physiology and pathology specifically developed for the study of neurodegenerative conditions, including Alzheimer’s, Parkinson’s and Huntington’s disease.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/13/2018 via BusinessWire

Certara, acquired Pirana Software

synopsis: Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence solutions, announced that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
buyer parent: Arsenal Capital Partners
buyer: Certara (:$261.77)
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. "
target: Pirana Software
Pirana is a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/12/2018 via BusinessWire

Certara, acquired Analytica Laser

synopsis: Certara, the global leader in model-informed drug development and regulatory science, announced that it has acquired Analytica Laser, a global research consultancy that uses health economics and outcomes research (HEOR) and real-world data to provide the highest level of scientific evidence of the value of medicines and health technologies.
buyer parent: Arsenal Capital Partners
buyer: Certara (:$261.77)
Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. "
target: Analytica Laser
Analytica Laser, a global research consultancy that uses health economics and outcomes research (HEOR) and real-world data to provide the highest level of scientific evidence of the value of medicines and health technologies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/1/2018 via BusinessWire

Certara, acquired BaseCase

synopsis: Certara, the global leader in model-informed drug development and regulatory science, announced that it has acquired BaseCase Management GmbH, a data visualization software as a service (SaaS) company headquartered in Berlin, Germany, with offices in New York.
buyer parent: Arsenal Capital Partners
buyer: Certara (:$261.77)
Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. "
target: BaseCase
BaseCase is a software as a service (SaaS) solution specializing in building interactive, spreadsheet-driven web-apps for the pharmaceutical, medical device and diagnostic industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/1/2015 via BusinessWire

Certara, acquired XenologiQ

synopsis: Certara, the global biosimulation technology-enabled drug development company, acquired XenologiQ, a UK-based quantitative systems pharmacology consultancy. XenologiQ's mission is to productively implement state-of-the-art modeling and simulation in medical and life sciences research.
buyer parent: Arsenal Capital Partners
buyer: Certara (:$261.77)
Certara is a global biosimulation technology-enabled drug development company. Certara’s solutions enable superior drug development and regulatory decision-making through biosimulation, thus increasing R&D productivity and commercial value. "
target: XenologiQ
XenologiQ is a UK-based consulting company. Its mission is to productively implement state-of-the-art modeling and simulation in medical and life sciences research. Its value proposition is to achieve this via the optimal integration of experience, technical excellence and global talent.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2014 via BNC Analysis

Synchrogenix Information Strategies, Inc. merged with Certara,

synopsis: Arsenal Capital Partners have acquired Synchrogenix Information Strategies Inc., which will merge with Certara LP. Synchrogenix, a specialty contract research organization providing strategic regulatory writing and related services to pharmaceutical, biotechnology, and medical device companies worldwide.
buyer parent: Arsenal Capital Partners
buyer: Certara (:$261.77)
Certara™ is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. "
target: Synchrogenix Information Strategies, Inc.
Synchrogenix is a specialty contract research organization providing strategic regulatory writing and related services to pharmaceutical, biotechnology, and medical device companies worldwide. The company offers pre-clinical, clinical, CMC, and drug safety writing and submission services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/13/2012 via BusinessWire

Certara, will acquire Simcyp Limited

synopsis: Certara has announced the completion of its acquisition of UK-based Simcyp Limited. Simcyp is a leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations, including pediatric populations.
buyer parent: Vector Capital
buyer: Certara (:$261.77)
Certara™ is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. "
target parent: Fusion IP plc
target: Simcyp Limited
Simcyp provides platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals (rat, dog and mouse).
price ($mm)
$32
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/4/2021 via GlobeNewswire

Certara, acquired Pinnacle 21

synopsis: Certara, Inc., a global leader in biosimulation, announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness.
buyer parent: EQT AB
buyer: Certara (:$261.77)
Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. "
target: Pinnacle 21
Pinnacle 21 is a global leader in software for preparing clinical trial data for regulatory submission. Their platform validates data quality and compliance with CDISC standards, enabling a clean data pipeline from worldwide sponsors to health authorities, including the FDA, PMDA and NMPA.
price ($mm)
$310
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/23/2020 via BusinessWire

Curi Bio, acquired Dana Solutions

synopsis: Curi Bio has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
buyer: Curi Bio
Curi Bio provides a seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. "
target: Dana Solutions
Dana Solutions is a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/2/2020 via BusinessWire

Simulations Plus, Inc., acquired Lixoft

synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has acquired Lixoft of Paris, France. Lixoft designs software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus is a premier developer of drug discovery and development software and is a provider of preclinical and clinical pharmacometric consulting services for regulatory submissions. The company also provides quantitative systems pharmacology models for liver-related injury and disease. "
target: Lixoft
Paris-based Lixoft designs software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. The company's Monolix Suite is a leading provider of population PKPD (Pharmacokinetic/Pharmacodynamic) modeling for pharmacometricians.
price ($mm)
$11
rev ($mm)
$4
EBITDA ($mm)
EV / rev
4.7x
EV / EBITDA
closed 1/8/2013 via Yahoo, Inc.

Elsevier B.V., acquired Aureus Sciences

synopsis: Elsevier announced the acquisition of Aureus Sciences, a Paris, France based privately held company that provides databases and information tools to pharmaceutical and biotech companies. Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets.
buyer parent: Reed Elsevier
buyer: Elsevier B.V.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles. "
target: Aureus Sciences
Aureus Sciences provides scientific databases and software applications for researchers involved in the drug discovery and development process.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/26/2012 via BusinessWire

Accenture, acquired Octagon Research Solutions, Inc.

synopsis: Accenture completed its acquisition of Octagon Research Solutions, a provider of clinical and regulatory information management solutions and software for the pharmaceutical industry. The acquisition enhances Accenture's existing clinical services capabilities – including clinical data management, clinical programming and safety case processing.
buyer: Accenture (ACN:$50,533.39)
Accenture is a global management consulting, technology services and outsourcing company. Accenture collaborates with clients to help them become high performance businesses and governments. "
target parent: Edison Ventures
target: Octagon Research Solutions, Inc.
Octagon Research Solutions is the world leader in clinical and regulatory information management solutions to the life sciences industry. Through an integrated suite of outsourced services, strategic consulting, and innovative technology, Octagon optimizes the entire drug development lifecycle.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/1/2021 via BNC Analysis

Astorg, Nordic Capital, acquired Cytel Inc.

synopsis: Nordic Capital, a Swedish private equity investor, and Astorg, a French private equity firm, have acquired Cytel Inc. from New Mountain Capital. Cytel is one of the largest providers of statistical software and advanced analytics for clinical trial design and biometrics execution.
buyer: Astorg
buyer: Nordic Capital
Nordic Capital is a Swedish private equity investor with a commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Paris-based Astorg is a leading independent private equity firm with over €9 billion of assets under management. "
target parent: New Mountain Capital, LLC
target: Cytel Inc.
Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution. Its experts deliver industry-leading software, data-driven analytics, real-world evidence, and strategic consulting.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/6/2019 via PE Hub

Catalyst Clinical Research, LLC, acquired Tri Stat

synopsis: Catalyst Clinical Research, LLC, a leading provider of clinical operation solutions to the biotechnology, pharmaceutical and medical device companies, has acquired Triangle Biostatistics, LLC (Tri Stat), a leading provider of statistical programming, statistical consulting, and data management services for the pharmaceutical industry.
buyer parent: NovaQuest
buyer: Catalyst Clinical Research, LLC
Catalyst Clinical Research is a leading provider of clinical operation solutions to the biotechnology, pharmaceutical and medical device companies. The company assists clients with their clinical development programs by providing therapeutically-aligned experts and teams and customized solutions. "
target: Tri Stat
Triangle Biostatistics (Tri Stat) is a leading provider of statistical programming, statistical consulting, and data management services for the pharmaceutical industry. Tri Stat provides strong statistical consulting and programming support utilizing the latest computing technology.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/2/2014 via BusinessWire

Cognigen Corporation merged with Simulations Plus, Inc.,

synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that the Agreement and Plan of Merger with Cognigen Corporation has been closed. Cognigen Corporation was founded in 1993 and has grown to become one of the leading providers of clinical trial data analysis.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. "
target: Cognigen Corporation
Cognigen Corporation is one of the leading providers of clinical trial data analysis. The company provides analysis and reports that are tailored to the expectations of regulatory agencies so that reports are submitted in a manner that minimizes follow-up questions from regulators.
price ($mm)
$5.20
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 2/6/2014 via BNC Analysis

Berry Consultants, LLC, will purchase FACTS from Tessella Ltd.

synopsis: Berry Consultants, a statistical consulting company specializing in the Bayesian approach to medical statistics, has reached an agreement with Tessella to acquire 100% ownership of FACTS. FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, versatile, and fastest clinical trial simulation tool on the market.
buyer: Berry Consultants, LLC
Berry Consultants is a statistical consulting company specializing in the Bayesian approach to medical statistics, an approach that is radically changing the way research is done throughout both device and drug development. "
seller: Tessella Ltd.
FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, versatile, and fastest clinical trial simulation tool on the market. It allows biostatisticians and clinical teams to rapidly design and compare innovative, advanced, clinical trial designs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2014 via PR Newswire

Evidera, acquired Archimedes, Inc.

synopsis: Symphony Technology Group (STG), a technology and services-focused private equity firm, and Evidera, a leading provider of evidence-based solutions for the healthcare industry, announced the acquisition of Archimedes, a San Francisco-based healthcare modeling company and wholly owned subsidiary of Kaiser Permanente.
buyer parent: Symphony Technology Group
buyer: Evidera
Evidera provides health economics, outcomes research, market access, data analytics and epidemiology services. Their research and consulting services are driven by world-class science and thought leadership and leverage a unique combination of capabilities. "
target parent: Kaiser Permanente
target: Archimedes, Inc.
Archimedes is a healthcare modeling and analytics organization. With the Archimedes Model at its core, the company enables people to combine real-world healthcare data and simulation data to create compelling and actionable evidence used in individual healthcare decision making.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/27/2013 via PR Newswire

Temis Text Intelligence, acquired i3 Analytics

synopsis: TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, announced that they have acquired the US-based i3 Analytics. i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data.
buyer: Temis Text Intelligence
In order to develop and market innovative Text Mining Solutions, TEMIS was founded in September 2000 by a team of managers, researchers and consultants from IBM. This skilled team had earlier developed and distributed IBM Text Mining solutions worldwide "
target: i3 Analytics
i3 Analytics is a provider of advanced data analytics and visualization technologies. Their Biopharma Navigator is an analytics tool that allow users to map clinical trials landscapes, scan the horizon for the latest news, and stay current on what researchers are doing.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/18/2012 via BusinessWire

Adjility Health will be merged with Alliance Life Sciences Consulting Group, Inc,

synopsis: Alliance Life Sciences Consulting Group (ALSCG), a leading management and technology consultancy, and Adjility Consulting, a consulting firm specializing in management consulting and analytic solutions for clinical operations and the global market access, pricing and reimbursement space, announced that the two companies will merge.
buyer: Alliance Life Sciences Consulting Group, Inc
Alliance Life Sciences Consulting Group employs more than 175 professionals who collectively understand the business challenges of the Life Sciences industry and offer solutions for Sales & Marketing, Managed Care & Government Contracting, Commercial Operations, Information Management and Analytics."
target: Adjility Health
Adjility Health is dedicated to helping healthcare companies improve their operations through the use of strategic consulting services and very industry domain-specific analytic, forecasting, predictive trending and other data insight tools.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/22/2009 via BusinessWire

Phase Forward, acquired Waban Software

synopsis: Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, announced that it has acquired privately held Waban Software, a leading provider of platform solutions for the automation and compliance of clinical data analysis and reporting, for $14 million in cash.
buyer: Phase Forward (PFWD:$0.00)
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture, clinical data management and clinical data analysis and reporting automation and compliance. "
target: Waban Software
Waban Software provides solutions that enable pharmaceutical and biotechnology companies to capture, integrate, manage and analyze life-sciences and clinical trial data.
price ($mm)
$12
rev ($mm)
$4
EBITDA ($mm)
EV / rev
3.5x
EV / EBITDA
announced 3/13/2012 via BusinessWire

Certara, will acquire Simcyp Limited

synopsis: Certara has announced the completion of its acquisition of UK-based Simcyp Limited. Simcyp is a leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations, including pediatric populations.
buyer parent: Vector Capital
buyer: Certara (:$261.77)
Certara™ is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. "
target parent: Fusion IP plc
target: Simcyp Limited
Simcyp provides platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals (rat, dog and mouse).
price ($mm)
$32
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/3/2008 via BusinessWire

Tripos, Inc., acquired Pharsight Corporation

synopsis: Tripos International, the leading provider of drug discovery informatics products and services, today announced that it has completed the acquisition of Pharsight Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development.
buyer parent: Vector Capital
buyer: Tripos, Inc.
Tripos combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. "
target: Pharsight Corporation (PHST:$28.34)
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
price ($mm)[EV]
$52 [$36]
rev ($mm)
$28
EBITDA ($mm)
$2
EV / rev
1.4x
EV / EBITDA
17.8x
closed 5/1/2006 via BusinessWire

PerkinElmer, Inc., acquired Spectral Genomics, Inc.

synopsis: PerkinElmer, Inc., a global technology leader in Health Sciences and Photonics, today announced the acquisition of the assets of Spectral Genomics, Inc., a leader in molecular karyotyping technology used to evaluate chromosomal abnormalities. Terms of the deal were not disclosed.
buyer: PerkinElmer, Inc. (PKI:$2,209.40)
PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. "
target: Spectral Genomics, Inc.
Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders.
price ($mm)
$12
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/16/2016 via PR Newswire

Indegene Lifesystems Pvt Ltd., acquired Wincere, Inc.

synopsis: Indegene, a global healthcare solutions provider, announced the acquisition of Wincere Inc. Wincere is a leading clinical data management and clinical and statistical programming solutions provider located on the West Coast in Silicon Valley, CA. Wincere is deeply engaged with clinical R&D needs of many emerging biopharma companies.
buyer: Indegene Lifesystems Pvt Ltd.
Indegene enables global healthcare organizations to address complex challenges by seamlessly integrating analytics, technology, operations and medical expertise and drives better health and business outcomes. "
target: Wincere, Inc.
Wincere provides smarter clinical research services across all clinical trial phases by using its patent-pending technology to support clinical trial startup, conduct, and submission activities.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/28/2020 via BusinessWire

Recursion Pharmaceuticals, Inc., acquired Vium, Inc.

synopsis: Recursion, a digital biology™ company leading in the industrialization of drug discovery, has announced its acquisition of Vium, a digital vivarium™ company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research.
buyer: Recursion Pharmaceuticals, Inc.
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, AI, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. "
target: Vium, Inc.
Vium is the first company to create a fully digital end to end Digital Vivarium® platform which is transforming in vivo research. The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/24/2020 via GlobeNewswire

Predictive Oncology Inc., will acquire Quantitative Medicine

synopsis: Predictive Oncology Inc. , a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is to acquire Quantitative Medicine, a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE.
buyer: Predictive Oncology Inc. (POAI:$1.38)
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. "
target: Quantitative Medicine
Quantitative Medicine is a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/15/2019 via BusinessWire

Instem, acquired Leadscope, Inc.

synopsis: Instem, a leading provider of IT solutions to the global life sciences market, announced that it has acquired Leadscope, a company that builds a chemoinformatics platform. Using Leadscope, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques.
buyer: Instem (AIM:INS:$38.90)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
target: Leadscope, Inc.
Leadscope builds a chemoinformatics platform. As a suite of tools, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques (prediction tools, scaffold generators, etc.).
price ($mm)
$4.10
rev ($mm)
$2
EBITDA ($mm)
$0
EV / rev
2.4x
EV / EBITDA
11.5x

Like Pinnacle 21


read more

Pinnacle 21

Comprehend Systems, Inc.

MDCPartners

karmadata

Dataline Software

eClinical Insights, Inc.

eResearch Technology, Inc.

etrials, Inc.

Relsys International, Inc.

Algorics

Bioinfogate S.L.

Allcyte

Medimix International

Patient Profiles, LLC

PharmaCM

Infotehna Group

Relay Technology Management

Cunesoft

Kneat Software

123Compliance Corporation

read more

Pinnacle 21

read more

Pinnacle 21

In Silico Biosciences, Inc.

Pirana Software

Analytica Laser

BaseCase

XenologiQ

Synchrogenix Information Strategies, Inc.

Simcyp Limited

read more

Pinnacle 21

Dana Solutions

Lixoft

Aureus Sciences

Octagon Research Solutions, Inc.

Cytel Inc.

Tri Stat

Cognigen Corporation

Tessella Ltd.

Archimedes, Inc.

i3 Analytics

Adjility Health

Waban Software

Simcyp Limited

Pharsight Corporation

Spectral Genomics, Inc.

Wincere, Inc.

Vium, Inc.

Quantitative Medicine

Leadscope, Inc.

Geography
Matching Companies
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2020
rev ($mm)
$38.90
EBITDA ($mm)
$6.31
EBIT ($mm)
$5.20
Net Income ($mm)
$3.13
Employees
304
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: SLP
 
 
 
 
 
 
 
 
Simulations Plus, Inc.
Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide.
year
2019
rev ($mm)
$35.84
EBITDA ($mm)
$12.38
EBIT ($mm)
$11.28
Net Income ($mm)
$9.11
Employees
109
  • drill down
  • watch
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: OTCPK:SYPT
 
 
 
 
 
 
 
 
Scrypt, Inc
Scrypt builds secure cloud-based workflow management and collaboration tools for regulated industries. They help businesses operating in regulated industries improve document workflow and regain valuable time while protecting business-critical information.
year
2009
rev ($mm)
$0.27
EBITDA ($mm)
($0.86)
EBIT ($mm)
($0.92)
Net Income ($mm)
Employees
7
  • drill down
  • watch
Ticker: ASX:PKS
 
 
 
 
 
 
 
 
Pacific Knowledge Systems
Pacific Knowledge Systems
Pacific Knowledge Systems (PKS) is an Australian provider of clinical expert intelligence. Their RippleDown solution integrates patient data with a knowledge base that is managed by clinical domain experts, to deliver patient-specific reports, recommendation and alerts.
year
2021
rev ($mm)
$6.12
EBITDA ($mm)
($0.30)
EBIT ($mm)
($0.35)
Net Income ($mm)
Employees
0
  • drill down
  • watch
Ticker: CHNG
 
 
 
 
 
 
 
 
Change Healthcare Corporation
Change Healthcare Corporation
Change Healthcare is a leading independent healthcare technology company that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system.
year
2020
rev ($mm)
$1,646.91
EBITDA ($mm)
EBIT ($mm)
($155.95)
Net Income ($mm)
Employees
15000
  • drill down
  • watch
Ticker: KERN
 
 
 
 
 
 
 
 
Akerna
Akerna
Akerna is a global regulatory compliance technology company in the cannabis space. Akerna’s service offerings include the MJ Platform, its leading seed-to-sale, regulatory compliance, technology solution, and Leaf Data Systems, which provide government clients with compliance technology solutions.
year
2020
rev ($mm)
$13.09
EBITDA ($mm)
($19.19)
EBIT ($mm)
($20.36)
Net Income ($mm)
Employees
136
  • drill down
  • watch
Ticker: OMCL
 
 
 
 
 
 
 
 
Omnicell, Inc.
Omnicell, Inc.
Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
year
2021
rev ($mm)
$914.37
EBITDA ($mm)
$99.36
EBIT ($mm)
$57.86
Net Income ($mm)
$35.01
Employees
2970
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: ASX:DTC
 
 
 
 
 
 
 
 
Damstra
Damstra
Damstra is a global leader in workforce management, compliance, and safety management. Through their unique, integrated workplace management platform, Damstra delivers powerful solutions that radically transform the way organisations manage, track and protect the entire workplace.
year
2021
rev ($mm)
$19.59
EBITDA ($mm)
($5.79)
EBIT ($mm)
($6.84)
Net Income ($mm)
Employees
90
  • drill down
  • watch
Ticker: MRCY
 
 
 
 
 
 
 
 
Mercury Computer Systems, Inc.
Mercury Computer Systems, Inc.
Mercury Computer Systems is the leading supplier of high-performance digital signal and image processing systems. These embedded computer systems transform streams of sensor data to visual information in real time for analysis and interpretation.
year
2011
rev ($mm)
$228.71
EBITDA ($mm)
$33.90
EBIT ($mm)
$25.55
Net Income ($mm)
$18.44
Employees
602
  • drill down
  • watch
Ticker: SYPT
 
 
 
 
 
 
 
 
Scrypt, Inc.
Scrypt, Inc.
Since 1998, Austin-based Scrypt, Inc. has been creating elegant document productivity tools for healthcare that eliminate manual processes and paper to save time and money. Scrypt has more than 30,000 customers across all 50 states.
year
2009
rev ($mm)
$0.27
EBITDA ($mm)
($0.85)
EBIT ($mm)
($0.91)
Net Income ($mm)
Employees
7
  • drill down
  • watch
Ticker: SLP
 
 
 
 
 
 
 
 
Simulations Plus, Inc.
Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide.
year
2019
rev ($mm)
$35.84
EBITDA ($mm)
$12.38
EBIT ($mm)
$11.28
Net Income ($mm)
$9.11
Employees
109
  • drill down
  • watch
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2020
rev ($mm)
$38.90
EBITDA ($mm)
$6.31
EBIT ($mm)
$5.20
Net Income ($mm)
$3.13
Employees
304
  • drill down
  • watch
Ticker: CHNG
 
 
 
 
 
 
 
 
Change Healthcare Corporation
Change Healthcare Corporation
Change Healthcare is a leading independent healthcare technology company that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system.
year
2020
rev ($mm)
$1,646.91
EBITDA ($mm)
EBIT ($mm)
($155.95)
Net Income ($mm)
Employees
15000
  • drill down
  • watch
Ticker: OMCL
 
 
 
 
 
 
 
 
Omnicell, Inc.
Omnicell, Inc.
Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
year
2021
rev ($mm)
$914.37
EBITDA ($mm)
$99.36
EBIT ($mm)
$57.86
Net Income ($mm)
$35.01
Employees
2970
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch